VetMedGuide

Vet Med Guide

Pharmaceuticals2026-05-14 · 9 min read

Bordetella Vaccine for Dogs: Boarding, Daycare, Grooming, and Route Differences

Intranasal vs oral vs injectable Bordetella vaccine for dogs — route differences, onset of immunity, AAHA and WSAVA recommendations, and what boarding facilities require.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Bordetella bronchiseptica is the primary bacterial pathogen in canine infectious respiratory disease complex (CIRDC), widely known as kennel cough. The Bordetella vaccine is classified as non-core by AAHA and WSAVA — meaning it is not recommended for every dog — but for dogs that board, attend daycare, visit groomers, or otherwise share air with other dogs, it is one of the most practically important vaccines in the preventive-care toolkit. The decision is less about whether to vaccinate and more about which formulation to use, when to give it relative to an upcoming boarding date, and what the evidence says about route-specific efficacy.

What Bordetella bronchiseptica causes

B. bronchiseptica is a gram-negative bacterium that colonizes the respiratory epithelium. It is one of multiple agents in CIRDC — others include canine parainfluenza virus (CPiV), canine adenovirus type 2 (CAV-2), canine herpesvirus, canine influenza virus, Streptococcus zooepidemicus, and Mycoplasma species. The characteristic presentation is a dry, honking cough that often worsens with exercise, excitement, or tracheal pressure. Most cases resolve without treatment, but B. bronchiseptica can progress to pneumonia, particularly in puppies, senior dogs, and immunocompromised patients.

Transmission occurs through direct contact (nose-to-nose), aerosolized droplets (coughing, sneezing, barking), and fomites (shared bowls, toys, surfaces). Dogs can shed B. bronchiseptica without showing clinical signs, which is why outbreaks can spread rapidly in congregate settings before any dog appears sick.

The incubation period is 3–10 days. Dogs are typically contagious before they start coughing.

Three routes, different immunology

There are three licensed Bordetella vaccine formulations in the United States, and the route of administration matters more than most owners realize.

Intranasal (IN)

Live avirulent B. bronchiseptica, administered as drops into the nares. Some intranasal products combine B. bronchiseptica with CPiV (bivalent) or with CPiV and CAV-2 (trivalent).

  • Onset of immunity: 48–72 hours after a single dose.
  • Dosing: One dose; no booster series needed for initial immunization.
  • Minimum age: As early as 3–4 weeks for some products (check label).
  • Duration of immunity: At least 12 months. One study demonstrated 13-month duration of immunity for an oral formulation; intranasal formulations have shown at least 1-year duration in published challenge studies.
  • Mechanism: Stimulates local mucosal immunity (IgA) in the upper respiratory tract, which is the site of natural infection. The common mucosal immune system produces antibodies directly where the pathogen enters.

The intranasal route may cause mild transient sneezing, nasal discharge, or coughing for 1–3 days after administration. This is expected and self-limiting.

AAHA's 2022 Canine Vaccination Guidelines note that the intranasal route may be preferable to oral for respiratory pathogens because of compartmentalization of mucosal immune responses — intranasal delivery stimulates more targeted respiratory-tract immunity than oral delivery. However, data from comparative studies are conflicting: one study showed equivalent protection between IN and oral routes, while another showed superior clinical efficacy for IN.

Oral

Live avirulent B. bronchiseptica, administered into the buccal pouch (between the cheek and gum). The first USDA-licensed oral Bordetella vaccine for dogs was introduced in the early 2010s. In January 2026, Elanco received USDA approval for TruCan Ultra B (Oral), a half-milliliter oral Bordetella vaccine — the first oral Bordetella product at a reduced volume, designed to improve patient comfort and reduce administration reactions.

  • Onset of immunity: Similar to intranasal — rapid, within 48–72 hours.
  • Dosing: One dose; no booster series.
  • Minimum age: Typically 8 weeks (check label).
  • Duration of immunity: At least 12 months.
  • Mechanism: Stimulates local mucosal immunity through the oral-nasal-associated lymphoid tissue.

A University of Wisconsin–Madison study comparing oral, intranasal, and parenteral Bordetella vaccines found that the oral vaccine provided protection equivalent to the intranasal vaccine and superior to the killed injectable vaccine in challenge studies. The practical advantage of the oral route is ease of administration — no need to handle the dog's nose, which some dogs resist.

A 2022 study in Frontiers in Veterinary Science evaluated the effects of intranasal and oral Bordetella vaccination on the olfactory capabilities of detection dogs. Neither route produced clinically significant hyposmia (loss of smell), though one combination (oral followed by intranasal at 28 days) showed a small but statistically significant increase in time to detection. The authors concluded that the risk of olfactory impairment from Bordetella vaccination is low.

Injectable (subcutaneous)

Killed whole-cell bacterin or cellular antigen extract. This is the oldest Bordetella vaccine formulation.

  • Onset of immunity: At least 5 days after the second dose (7+ days total).
  • Dosing: Two doses, 2–4 weeks apart. A single dose does not immunize.
  • Minimum age: Typically 8 weeks.
  • Duration of immunity: Approximately 12 months after the two-dose series.
  • Mechanism: Stimulates systemic IgG but not mucosal IgA. This is the key limitation — the immune response is not targeted to the respiratory mucosa where infection begins.

The killed injectable formulation is generally considered the least effective of the three routes. The 2022 AAHA guidelines and the WSAVA 2024 guidelines both recommend mucosal (IN or oral) vaccination over parenteral for Bordetella. The injectable route may still be appropriate for dogs that cannot receive live vaccines or for owners who strongly prefer injectable administration.

Important safety note: The WSAVA 2024 guidelines emphasize that live Bordetella vaccines intended for intranasal or oral administration must never be inadvertently injected parenterally, as this can cause a severe adverse reaction.

What AAHA and WSAVA recommend

AAHA classifies Bordetella as a non-core (lifestyle) vaccine. The 2022 AAHA Canine Vaccination Guidelines recommend annual mucosal vaccination for dogs expected to board, be shown, or enter a kennel situation within 6 months of vaccination. UC Davis School of Veterinary Medicine similarly recommends annual mucosal vaccination for dogs with anticipated congregate exposure.

WSAVA's 2024 Vaccination Guidelines classify Bordetella as non-core and recommend mucosal vaccination (single dose, annual revaccination) for at-risk dogs.

Neither AAHA nor WSAVA specifies a preferred route between intranasal and oral. Both note that available commercial vaccines "all work at some level" regardless of route, but that mucosal routes provide faster onset and better protection than the killed injectable product.

When to vaccinate relative to boarding

Most boarding facilities and daycares require Bordetella vaccination within the past 6–12 months. This is a facility policy, not a veterinary standard — there is no universal requirement.

Timing recommendations:

  • Mucosal vaccines (IN or oral): Administer at least 1 week before boarding to allow immunity to develop. Most facilities accept vaccination given within 7–14 days prior.
  • Injectable vaccine: The two-dose series takes 4–6 weeks to complete. Plan well in advance if this is the chosen route.
  • Annual versus semiannual: Some facilities require Bordetella every 6 months. There is no published evidence that semiannual vaccination provides better protection than annual. This is a facility policy, not a veterinary recommendation.

If your dog needs boarding on short notice, a mucosal vaccine provides the fastest route to protection.

What the vaccine does and does not do

No Bordetella vaccine provides sterilizing immunity. A vaccinated dog can still contract kennel cough. What vaccination does:

  • Reduces the severity of clinical signs.
  • Shortens the duration of illness.
  • Reduces the period of contagious shedding.
  • Lowers the probability of progression to pneumonia.

CIRDC is a multi-pathogen syndrome. Even with Bordetella vaccination, a dog can develop kennel cough from parainfluenza, adenovirus, influenza, or other agents. Some intranasal Bordetella vaccines include CPiV and CAV-2 for broader respiratory protection.

Grooming, dog parks, and other exposures

The Bordetella decision is not binary — boarding versus never leaving the house. Dogs are exposed to respiratory pathogens at:

  • Dog parks: Nose-to-nose contact, shared water bowls, aerosolized droplets in enclosed areas.
  • Grooming salons: Dogs held in close proximity, often in enclosed spaces with recirculated air.
  • Veterinary waiting rooms: Gathering point for dogs with active respiratory infections.
  • Training classes: Puppies grouped by age, close contact during socialization exercises.
  • Dog shows and competitions: High density, high stress, shared equipment.

A dog that attends any of these regularly may benefit from Bordetella vaccination even if it never boards overnight. The decision should be part of an annual lifestyle discussion with your veterinarian.

Dogs that should not receive live Bordetella vaccines

Because intranasal and oral Bordetella vaccines contain live avirulent bacteria, they should be used with caution in:

  • Immunocompromised dogs (dogs receiving chemotherapy, immunosuppressive therapy, or with confirmed immune deficiency).
  • Dogs in households with immunocompromised humans. Live Bordetella vaccine strain is shed in nasal and oral secretions for a period after vaccination. The risk to immunocompromised humans is considered very low but not zero. Killed injectable Bordetella may be preferred in these households.
  • Pregnant bitches. Live bacterial vaccines are generally avoided during pregnancy.

What to ask your veterinarian

  • Does my dog's lifestyle warrant Bordetella vaccination? How often?
  • Which Bordetella formulation does the practice carry — intranasal, oral, or injectable? Is a combination product available?
  • If my dog needs to board next week, which route gets us protection fastest?
  • Does the practice's Bordetella vaccine include parainfluenza and/or adenovirus, or is it monovalent?
  • My boarding facility requires Bordetella every 6 months — is that supported by evidence, or is annual sufficient?

Sources

Topics
Vaccination & Infectious Disease
Related Articles